ALUR•benzinga•
Allurion Technologies Announces New Study On Allurion Balloon And GLP-1 Agonists To Boost Long-Term Tolerability And Adherence; Previous Studies Show 30% GLP-1 Discontinuation in First Month, 58% Overall
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 18, 2025 by benzinga